Dr Palle Osther is currently Professor at the Department of Urology, Fredericia Hospital – a part of Hospital Littlebelt, in Denmark, and the Director of the Urological Research Center at Hospital Littlebelt, University of Southern Denmark. His research interests focus on urolithiasis, minimal-invasive treatments for urinary stone disease, urinary tract pain and prostate cancer. In his clinical practice, he mainly deals with urinary stone disease and upper urinary tract pathology, including endoscopic procedures for benign and malignant urological diseases. In his areas of interest he has published extensively, and he has had numerous scientific presentations world-wide.
Selected publications from PubMed
Evaluation of a Methylated Circulating Tumour DNA Panel for Detection and Disease Stratification in Prostate Cancer.
Eriksen SV, Zedan AH, Kahns S, Osther PJS, Timm S, Hansen TF
Int J Mol Sci. 2026 Jul 7;27(13) doi: 10.3390/ijms27136081.
Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer.
Kondrup K, Iisager L, Salachan PV, Nørgaard M, Lamy P, Eeles R, Hansen TF, Osther PJS, Zedan AH, Borre M, Sørensen KD
Br J Cancer. 2026 Jul;135(1):127-138 doi: 10.1038/s41416-026-03432-y.
Proclarix' performance in ruling out patients with no or indolent prostate cancer: evaluation in a Danish population.
Schiess R, Athanasiou A, Kasten MME, Hansen TF, Kissow GE, Obro LF, Madsen JS, Poulsen MH, Osther PJ, Zedan AH
BMC Cancer. 2026 May 9;26(1) doi: 10.1186/s12885-026-16118-8.
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.
Bancroft EK, Page EC, McHugh J, Thomas S, Taylor N, Pope J, Evans DG, Rothwell J, Grindedal EM, Maehle L, James P, McKinley J, Mascarenhas L, Side L, Thomas T, van Leerdam ME, van Asperen CJ, Kiemeney LALM, Ringelberg J, Vlaming M, Rønlund K, Osther PJS, Helfand BT, Hutten CG, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams WAG, Cook J, Rosario DJ, Maxwell K, Powers J, Buys S, Lyman J, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, Davidson R, Longmuir M, Ruijs MWG, Blom EW, van Engelen K, Williams R, Andrews L, Murphy DG, Saya S, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Snape K, Gowie M, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Cajal TRY, Krajc M, Cleaver R, Cruellas M, Perez-Ballestero E, Brady AF, Gallagher D, Donaldson A, Barwell J, Nicolai N, Friedman E, Hall MJ, Greenhalgh L, Murthy V, Copakova L, McGrath JS, Cooke P, Arun B, Myhill K, Hogben M, Hussain S, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Falconer A, Gronberg H, Hamdy FC, Khoo V, Lilja H, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Offman J, Rennert G, Suri M, Dudderidge T, IMPACT Study Collaborators, Brook MN, Kote-Jarai Z, Eeles RA
Eur Urol. 2026 May;89(5):457-468 doi: 10.1016/j.eururo.2026.01.031.
The Prognostic Value of Proclarix in Prostate Cancer Patients Under Active Surveillance: Predicting Transition to Active Treatment and Disease Progression in a Danish Cohort.
Athanasiou A, Hansen TF, Madsen JS, Poulsen MH, Mortensen MA, Kissow GE, Øbro LF, Osther PJ, Schiess R, Zedan AH
Cancers (Basel). 2026 Apr 23;18(9) doi: 10.3390/cancers18091348.
Help your network discover Dr. Palle Osther's clinical expertise.
